Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 6/20 | 0.46 |
| ▸ | PLD2 | O14939 | 2/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950573 | 0.98 | OPRK1 (0.47) | OPRK1CTSBCTSSCTSKPLD1 | |
| SCHEMBL5950194 | 0.94 | OPRK1 (0.46) | OPRK1CTSBCTSSCTSKPLD1 | |
| SCHEMBL5950642 | 0.92 | OPRK1 (0.46) | OPRK1CTSBCTSSCTSKPLD1 | |
| SCHEMBL6632646 | 0.85 | PLD2 (0.46) | OPRK1CTSBCTSSCTSKPLD1 | |
| SCHEMBL5780094 | 0.85 | CTSB (0.58) | OPRK1CTSBCTSSCTSKPLD1 | |
| SCHEMBL5950215 | 0.84 | OPRK1 (0.53) | OPRK1CTSBCTSSCTSKPLD1 | |
| SCHEMBL5950574 | 0.82 | ITGB1 (0.49) | OPRK1CTSBCTSSCTSKPLD1 | |
| SCHEMBL5780364 | 0.81 | OPRK1 (0.49) | OPRK1CTSBCTSSCTSKPLD1 | |
| SCHEMBL5779538 | 0.79 | OPRK1 (0.51) | OPRK1CTSBCTSSCTSKPLD1 | |
| SCHEMBL5950196 | 0.79 | OPRK1 (0.51) | OPRK1CTSBCTSSCTSKPLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241132-A1 | Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1489081-A1 | SPIRO DERIVATIVES AND ADHESION MOLECULE INHIBITORS COMPRISING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241132-A1 | Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient | VCAM1, SELL, ICAM1 | OPRK1 2459/4885CTSB 2883/4885CTSS 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.